US EditionPublished • loading... • Updated
Health Canada grants Palisade NOL for trial of PALI-2108 in FSCD - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Health Canada grants Palisade NOL for trial of PALI-2108 in FSCD - BioTuesdays
Palisade Bio (NASDAQ: PALI) has announced receiving a No Objection Letter (NOL) from Health Canada for its clinical trial application to evaluate PALI-2108, a first-in-class, ileocolonic-targeted PDE4 B/D inhibitor, in a Phase 1b study for the treatment of fibrostenotic Crohn’s disease (FSCD). According to Palisde, dosing is expected to begin in the second half of 2025, with topline safety, PK, and PD readouts anticipated in the first quarter of…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
